We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Simple Urine Test Could Detect Multiple Cancers at Early Stage

By LabMedica International staff writers
Posted on 25 Jun 2025

When disease is present, the human body releases tiny molecules known as volatile organic compounds (VOCs). Now, a spectroscopy and artificial intelligence (AI)-powered urine-based test uses scent-based technology for the routine and noninvasive detection of cancer-related VOCs.

TOBY, Inc. (New York City, NY, USA) has developed a single urine test that detects 10 cancers, representing over 60% of all new cases globally. This test identifies the unique molecular signature of cancer by combining the precision of spectroscopy, changes in biomarkers (VOCs), and cutting-edge computational algorithms to deliver early, easy, and affordable cancer screening. The process begins with spectroscopy, analyzing the molecular signature of VOCs in urine. These signatures reflect real-time changes in physiology and metabolism. The company’s proprietary AI interprets this complex data to identify early patterns of disease, often before symptoms appear. These algorithms are the result of deep research, development, and training on diverse biological signatures. Every model is engineered to learn from high-dimensional data, capturing subtle, disease-specific patterns with remarkable precision.


Image: The spectroscopy and AI-powered urine-based test detects 10 cancers (Photo courtesy of 123RF)
Image: The spectroscopy and AI-powered urine-based test detects 10 cancers (Photo courtesy of 123RF)

Unlike traditional diagnostics that rely on imaging or genetic sequencing, this test focuses on what the body emits in the moment. This approach is fast, scalable, and noninvasive—offering a new pathway for early detection across multiple cancer types. Instead of just detecting cancer, the test interprets the body’s chemical signals using a single, simple urine sample and turns them into actionable insights. TOBY combine truly noninvasive sampling, advanced spectroscopy, and AI for a uniquely accurate, accessible cancer test for multiple cancers.

"Our goal is to support earlier detection, when treatment is most effective and the burden on patients and the healthcare system is reduced," said Dragan Sebišanović, Chief Science Officer of TOBY. "Our technology uses machine learning to help identify molecular patterns associated with early-stage cancer."

Related Links:
TOBY, Inc.


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Automated Biochemical Analyzer
iBC 900

Latest Clinical Chem. News

New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
25 Jun 2025  |   Clinical Chem.

New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
25 Jun 2025  |   Clinical Chem.

Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
25 Jun 2025  |   Clinical Chem.



PURITAN MEDICAL